ArticleFrontiers in pediatrics2026
Surpassing genetic height potential at final adult height after monthly depot leuprolide therapy in Taiwanese girls with central precocious or early puberty: a ROC-based analysis.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gonadotropin-releasing hormone agonists (GnRHa) are widely used to treat central precocious puberty (CPP), yet long-term outcomes based on confirmed final adult height (FAH) remain limited, particularly in Asian populations. Whether GnRHa therapy enables patients to surpass their genetically predicted height potential has not been well established. Methods: This retrospective cohort study included 250 girls with central precocious puberty (CPP) or early puberty treated with depot leuprolide acetate (3.75 mg every 4 weeks) at Chang Gung Memorial Hospital (2003-2023). Among 84 patients with confirmed FAH, 73 were included after excluding those receiving growth hormone. Patients were categorized as FAH > mid-parental height (MPH) or FAH ≤ MPH. Clinical and auxological variables were analyzed, and ROC analysis evaluated the predictive value of age at treatment initiation. Results: Among 73 patients, 39 (53.4%) achieved FAH exceeding MPH. These patients were younger at treatment initiation, had greater bone age advancement, and higher baseline height SDS, while absolute height was similar. During therapy, they maintained superior height SDS and growth velocity, resulting in a 6.57 cm greater FAH ( Conclusion: In conclusion, GnRHa therapy is associated with favorable height outcomes in a subset of patients, particularly with earlier initiation and sustained growth during treatment. These findings support a prognostic, individualized approach emphasizing skeletal maturity, pubertal tempo, and longitudinal growth monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.